CAMBRIDGE, Mass., Jan. 3 /CNW/ -- Mersana, a cancer therapeutics company,
announced today the appointment of C. Boyd Clarke as Chairman of the Company's
Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical
executive with a significant record of accomplishment over a 30-year industry
"It is a great pleasure to welcome Boyd Clarke as Chairman of our Board
of Directors," said Julie A. Olson, PhD, President and Chief Executive Officer
at Mersana. "Boyd brings diverse management experience and commercial
expertise in areas important to Mersana at our stage of development. His
skills complement those of our existing team very well, and we anticipate his
strategic leadership will be of considerable value as we advance our
Over the past 11 years Mr. Clarke has held the role of Chairman and Chief
Executive Officer at several publicly-held biotechnology companies, most
recently Neose Technologies. During his four year tenure at Neose, Mr. Clarke
led the company from a platform-based discovery operation to a clinical stage
development company with multiple product candidates. As President and CEO of
Aviron he oversaw the Biological Licensing Application (BLA) submission for
the company's lead product and ultimately secured the sale of the vaccine
company to MedImmune. He also served as President and CEO of US Bioscience.
Mr. Clarke began his pharmaceutical career at Merck, where he held a series of
increasingly responsible positions, including President of Pasteur Merieux MSD
and Vice President of Merck Vaccines. He holds a Bachelor of Science degree
and a Master of Arts degree from the University of Calgary. Mr. Clarke serves
on the Board of Directors of QLT, Inc. and Rib-X, and is a past board member
of the Biotechnology Industry Association (BIO).
"Mersana's Fleximer(R) technology has the potential to create safer and
more efficacious cancer drugs, and the promise of the technology is now being
demonstrated in their ongoing clinical studies," stated Boyd Clarke. "I'm
excited by the Company's prospects and am looking forward to participating in
their continued growth as Chairman."
About Mersana Therapeutics, Inc.
Mersana, a privately held, venture backed company, utilizes its
proprietary nanotechnology platform to transform existing and experimental
anti-cancer agents into new, patentable drugs with superior pharmaceutical
properties. The key component of Mersana's platform is Fleximer(R), a novel,
biodegradable and bio-inert material that can be chemically linked to small
molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-
camptothecin conjugate, which is currently in Phase 1 clinical trials and
several preclinical stage oncology compounds. Mersana's investors include
Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris
Group and PureTech Ventures.
Fleximer(R) is a trademark of Mersana Therapeutics, Inc.
For further information:
For further information: Pete Leone, Chief Operating Officer of Mersana
Therapeutics, Inc., +1-617-498-0020; or Media, Kathryn Morris of KMorrisPR,
+1-845-635-9828, firstname.lastname@example.org, for Mersana Therapeutics, Inc.